To clinically evaluate the efficacy of patient- and/or donor-derived probiotics in ameliorating intestinal flora dysbiosis in patients with acute intestinal graft-versus-host disease (aGVHD), thereby mechanistically enhancing clinical outcomes and quality of life through intestinal microbiome modulation.
Age >50 years, regardless of gender;
Scheduled for haploidentical hematopoietic stem cell transplantation;
ECOG performance status score ≤2;
Voluntarily participate and provide written informed consent.
Active or chronic infectious diseases, including recent febrile symptoms (axillary temperature ≥37.3°C within 48h);
Clostridioides difficile infection (CDI): Recurrent or refractory CDI;
Other conditions: Ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS), diarrhea associated with dysbiosis, liver cirrhosis;
Antibiotic usage within 7 days prior to enrollment.